Gabapentin · oral capsule
Analgesics
Approved uses
Postherpetic neuralgia
Day 1: a single 300 mg dose. Day 2: 600 mg/day in two doses. Day 3: 900 mg/day in three doses. Titrate as needed up to 1,800 mg/day
The reason this card matters in eye care: postherpetic neuralgia after herpes zoster ophthalmicus
Partial onset seizures, adjunctive therapy, age 12 and over
Start at 300 mg three times daily; may be titrated up to 600 mg three times daily
Contraindications
Demonstrated hypersensitivity to gabapentin or its ingredients
Capsules 100 mg, 300 mg, 400 mg; tablets 600 mg, 800 mg; bottles of 100. Oral solution 250 mg per 5 mL, 470 mL bottle
The precise mechanism by which Gabapentin produces its analgesic and antiepileptic action are unknown. Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake, or degradation. In vitro studies have shown that Gabapentin binds with high-affinity to the α2δ subunit of voltage-activated calcium channels; however, the relationship of this binding to the therapeutic effects of gabapentin is unknown.
Warnings & Precautions
- DRESS/Multiorgan hypersensitivity: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has occurred with NEURONTIN, and some of these reactions have been fatal or life-threatening. Early manifestations such as fever or lymphadenopathy may be present even though rash is not evident. If such signs or symptoms are present, evaluate the patient immediately, and discontinue NEURONTIN if an alternative etiology cannot be established.
- Anaphylaxis and angioedema: NEURONTIN can cause anaphylaxis and angioedema after the first dose or at any time during treatment. Signs have included difficulty breathing, swelling of the lips, throat, and tongue, and hypotension requiring emergency treatment. Patients should discontinue NEURONTIN and seek immediate medical care should they experience signs or symptoms of anaphylaxis or angioedema.
- Driving impairment: Driving performance studies with a prodrug of gabapentin indicate that gabapentin may cause significant driving impairment, and patients' ability to assess their own driving competence can be imperfect. Patients should not drive or operate complex machinery until they have gained sufficient experience to assess whether NEURONTIN impairs their ability.
- Somnolence/sedation and dizziness: NEURONTIN causes somnolence and dizziness. Observe patients for signs of CNS depression when NEURONTIN is used with other drugs with sedative properties. Patients who require concomitant morphine may have increased gabapentin concentrations and may require dose adjustment.
- Suicidal behavior and ideation: Antiepileptic drugs, including NEURONTIN, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Monitor for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Suicidal behavior and ideation have also been reported after discontinuation.
- Increased risk of seizures: Antiepileptic drugs should not be abruptly discontinued because of the possibility of increasing seizure frequency. Taper the dose over at least a one-week period. Withdrawal symptoms have been observed in some patients after discontinuation.
- Status epilepticus: Status epilepticus occurred in epilepsy studies. Because adequate historical data are not available, it is impossible to say whether NEURONTIN is associated with a higher or lower rate than expected.
- Respiratory depression: Gabapentin has been associated with serious, life-threatening, or fatal respiratory depression when coadministered with CNS depressants, including opioids, or in the setting of underlying respiratory impairment. When NEURONTIN is co-prescribed with another CNS depressant, particularly an opioid, or prescribed to patients with underlying respiratory impairment, monitor for respiratory depression and sedation, and consider initiating NEURONTIN at a low dose.
- Neuropsychiatric adverse reactions: Use in pediatric patients with epilepsy 3 to 12 years of age is associated with emotional lability, hostility including aggressive behaviors, thought disorder, and hyperkinesia. Most of the reactions were mild to moderate in intensity. Monitor for such events.
- Tumorigenic potential: Gabapentin increased the incidence of pancreatic acinar cell tumors in rats. The clinical significance of this finding is unknown.
Common Side Effects
Postherpetic neuralgia: the most common adverse reactions in adults, not seen at an equivalent frequency among placebo-treated patients, were dizziness, somnolence, and peripheral edema. Epilepsy in patients over 12 years of age: the most common adverse reactions with NEURONTIN in combination with other antiepileptic drugs, not seen at an equivalent frequency among placebo-treated patients, were somnolence, dizziness, ataxia, fatigue, and nystagmus. Epilepsy in pediatric patients 3 to 12 years of age: the most common adverse reactions with NEURONTIN in combination with other antiepileptic drugs, not seen at an equal frequency among placebo-treated patients, were viral infection, fever, nausea and/or vomiting, somnolence, and hostility.
Pregnancy: Published cohort studies have not indicated an increased risk of major birth defects or miscarriage, but methodological limitations hinder interpretation. In mice, rats, and rabbits, gabapentin was developmentally toxic at doses similar to or lower than those used clinically. Postmarketing data suggest that extended gabapentin use with opioids close to delivery may increase the risk of neonatal withdrawal versus opioids alone; observe neonates exposed to NEURONTIN and opioids for signs and symptoms of neonatal withdrawal. Encourage enrollment in the NAAED Pregnancy Registry.
Lactation: Gabapentin is secreted in human milk following oral administration. The effects on the breastfed infant and on milk production are unknown. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for NEURONTIN and any potential adverse effects on the breastfed infant.
Safety and effectiveness of gabapentin in the management of postherpetic neuralgia in pediatric patients have not been established. Safety and effectiveness as adjunctive therapy in the treatment of partial seizures in pediatric patients below the age of 3 years has not been established.